Outset Medical, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Outset Medical Outset Medical, Inc. (OM) is a medical technology company that develops and commercializes the Tablo Hemodialysis System, an all-in-one, connected platform designed to simplify dialysis treatments across the care continuum from hospital ICUs and outpatient clinics to home settings; the system supports multiple modalities including hemodialysis, features automated setup and teardown processes, cloud-based data streaming for remote monitoring and reporting, and rapid training capabilities for nurses in hours and patients in days. Headquartered in San Jose, California, and founded in 2003, the company manufactures in North America and primarily operates throughout the United States, targeting healthcare providers, hospitals, dialysis clinics, and end-stage renal disease patients with its innovative renal care solutions that aim to reduce costs, complexity, and improve patient outcomes through clinical versatility and digital health integration. In early 2025, Outset Medical announced a one-for-fifteen reverse stock split effective March 20 to reduce shares outstanding and support strategic objectives; later in January 2025, it secured up to $169 million in private placement financing led by Perceptive Advisors and others including T. Rowe Price and Durable Capital Partners LP, alongside a new $100 million term loan facility maturing in 2030 to retire $200 million in prior debt, enhancing its liquidity to approximately $210 million post-transaction while reporting preliminary 2024 revenues of $113 million.
Outset Medical, Inc. (NASDAQ: OM) Investor Alert: Schubert Jonckheer Investigating Possible False Statements, Over $50 Million in Insider Sales
Outset Medical Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Outset Medical (OM) Surges 25.6%: Is This an Indication of Further Gains?
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 2026
Osisko Intersects 80 Metres Averaging 1.93% Cu at Gaspé
Did Outset Medical, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Osisko Metals Files NI 43-101 Technical Report for the Gaspé Copper Project
Osisko Metals Announces Results of Voting at 2026 Annual Meeting of Shareholders and Welcomes Keith McKay to the Board
Outset Medical Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Outset Medical to Present at RBC Global Healthcare Conference
Outset Medical, Inc. (OM) Q1 2026 Earnings Call Transcript
Outset Medical Q1 Earnings Call Highlights
Outset Medical, Inc. (OM) Reports Q1 Loss, Lags Revenue Estimates
Outset Medical Reports First-Quarter Results
Outset Medical to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026
Contrasting EUDA Health (NASDAQ:EUDA) and Outset Medical (NASDAQ:OM)
Did Outset Medical, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Outset Medical Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Outset Medical Names Derick Elliott as Executive Vice President of Commercial
Outset Medical, Inc. (NASDAQ:OM) Given Average Recommendation of “Moderate Buy” by Analysts